IPO - INTENSITY THERAPEUTICS, INC.

Form Type: 424B4

Filing Date: 2025-04-25

Corporate Action: Ipo

Type: New

Accession Number: 000162828025020056

Filing Summary: Intensity Therapeutics, Inc. filed a prospectus for an initial public offering (IPO) of 3,133,333 shares of common stock and accompanying Series B-1 and Series B-2 Common Warrants to purchase additional shares. The shares are priced at $0.75 each, with warrants exercisable at $0.85, and the offering seeks approximately $1.9 million in net proceeds for funding ongoing clinical studies and operational expenses. The company is involved in late-stage clinical biotechnology, focusing on localized cancer therapies and has recently conducted trials showing significant efficacy in reducing tumor size and promoting immune activation. The offering is facilitated through placement agents A.G.P./Alliance Global Partners and Brookline Capital Markets with no established market for the warrants. The stock is listed on Nasdaq under the symbol 'INTS.' The expected closing date for the offering is April 28, 2025.

Form Type: 8-K

Filing Date: 2025-04-25

Corporate Action: Ipo

Type: New

Accession Number: 000162828025020057

Filing Summary: On April 24, 2025, Intensity Therapeutics, Inc. commenced a public offering of 3,133,333 shares of common stock at a price of $0.75 each, alongside 3,133,333 Series B-1 Common Warrants and 3,133,333 Series B-2 Common Warrants. The warrants have exercise prices of $0.85 and are immediately exercisable, with varying expiration periods of five years for the Series B-1 and eighteen months for the Series B-2. The estimated net proceeds from the offering are around $1.9 million, intended for patient enrollment in the INVINCIBLE-4 study, treatment of existing patients in the INVINCIBLE-3 study, and general corporate purposes. The offering is set to close on or about April 28, 2025, pending customary conditions. The company has established a Securities Purchase Agreement with institutional investors containing restrictions on stock issuance for 30 days post-offering. The warrants are subject to ownership limitations of 4.99%, adjustable to 9.99% with prior notice. A placement agreement was signed with A.G.P. and Brookline Capital Markets for leading and co-placement services in the offering, with a fee structure set at 7.0% of gross proceeds plus certain reimbursable expenses.

Form Type: S-1/A

Filing Date: 2025-04-24

Corporate Action: Ipo

Type: New

Accession Number: 000162828025019491

Filing Summary: Intensity Therapeutics, Inc. filed an amendment to its registration statement on Form S-1 on April 24, 2025, proposing an initial public offering (IPO) of securities. The company aims to sell up to 2,307,692 shares of common stock at an assumed public offering price of $1.30 per share, concurrent with warrants to purchase additional shares. The registration statement allows for a mixture of common stock, Series B-1 and B-2 common warrants, and pre-funded warrants to be sold in one continuous offering process. This could result in an overall offering size of up to 4,615,384 shares. Intensity Therapeutics is positioned as a late-stage clinical biotechnology company focused on localized cancer treatment aimed at fostering anti-cancer immune activation. Their lead product candidate, INT230-6, utilizes a novel delivery method that combines powerful anti-cancer agents with amphiphilic compounds to enhance treatment efficacy. Recent trials, including Phase 1/2 and Phase 2 studies, showcase significant potential results in reducing tumor sizes. The company is also prioritizing securing funding for ongoing clinical trials and future studies involving INT230-6, especially for patients with specific types of cancer. The anticipated completion of this offering is around April 30, 2025, and involves a structured payment and delivery mechanism through placement agents. The document emphasizes the high level of interest and the financial projections regarding the company’s innovative cancer treatment approach.

Form Type: S-1

Filing Date: 2025-04-22

Corporate Action: Ipo

Type: New

Accession Number: 000162828025018892

Filing Summary: Intensity Therapeutics, Inc. is filing a registration statement under the Securities Act of 1933 for an initial public offering (IPO) of its common stock. The company intends to sell up to 4,255,319 shares of common stock, accompanied by common warrants, as part of this offering. The shares and corresponding warrants are set to be offered at a public offering price of $1.88 based on the last reported sale price of its common stock on Nasdaq. The offering includes various types of warrants, with pre-funded warrants available for certain purchasers to circumvent ownership limits. The proceeds from the offering are aimed at advancing the company's pipeline of drug candidates, specifically targeting localized cancer treatment through innovative delivery mechanisms that induce systemic immune activation. The registration statement requires effectiveness under SEC regulations before any securities can be sold.

Form Type: DRS

Filing Date: 2025-03-28

Corporate Action: Ipo

Type: New

Accession Number: 000162827925000170

Filing Summary: On March 28, 2025, Intensity Therapeutics, Inc. filed a draft registration statement with the SEC for a public offering of up to shares of common stock, common warrants, and pre-funded warrants. This offering is conducted on a best-efforts basis, and the shares, warrants, and warrants are to be priced and sold together, with certain purchasers being offered pre-funded warrants in cases of potential over-ownership. The offering has no minimum requirement, allowing for the possibility of raising less than expected, impacting business goals. The document outlines the intended proceeds, use of funds, and includes risk factors for potential investors. The filing emphasizes the confidentiality and preliminary nature of the registration statement, indicating that it has not yet been publicly filed for sale, with the aim of ongoing investor engagement and follow-up for funding considerations.